Editing Genentech (section)

==Controversy==

===Disputes===
In November 1999, Genentech agreed to pay the [[University of California, San Francisco]] $200 million to settle a nine-year-old patent dispute. In 1990, UCSF sued Genentech for $400 million in compensation for alleged theft of technology developed at the university and covered by a 1982 patent.{{Citation needed|date=January 2020}} Genentech claimed that they developed [[Protropin]] (recombinant [[somatotropin]]/human growth hormone), independently of UCSF. A jury ruled that the university's patent was valid in July 1999, but wasn't able to decide whether Protropin was based upon UCSF research or not. Protropin, a drug used to treat [[dwarfism]], was Genentech's first marketed drug and its $2 billion in sales has contributed greatly to its position as an industry leader.{{Citation needed|date=January 2020}} The settlement was to be divided as follows: $30 million to the [[University of California finances|University of California General Fund]], $85 million to the three inventors and two collaborating scientists, $50 million towards a new teaching and research campus for UCSF, and $35 million to support university-wide research.<ref>{{cite news|last=Genentech Press Release|title=University of California and Genentech Settle Patent Infringement Lawsuits|url=http://www.gene.com/media/press-releases/4887/1999-11-19/university-of-california-and-genentech-s|work=Genentech, Inc.|access-date=November 16, 2015|archive-url=https://web.archive.org/web/20130822221538/http://www.gene.com/media/press-releases/4887/1999-11-19/university-of-california-and-genentech-s|archive-date=August 22, 2013|url-status=dead}}</ref>

In 2009, ''[[The New York Times]]'' reported that Genentech's talking points on [[Health care reform in the United States|health care reform]] appeared verbatim in the official statements of several Members of [[U.S. Congress|Congress]] during the national health care reform debate.<ref>Pear, Robert. [https://www.nytimes.com/2009/11/15/us/politics/15health.html?pagewanted=2&_r=1&adxnnl=1&ref=politics&adxnnlx=1258294232-7WmWloVRzvQfa4/As1ohkQ "In House, Many Spoke with One Voice: Lobbyists"] {{Webarchive|url=https://web.archive.org/web/20190831230026/https://www.nytimes.com/2009/11/15/us/politics/15health.html?pagewanted=2&_r=1&adxnnl=1&ref=politics&adxnnlx=1258294232-7WmWloVRzvQfa4%2FAs1ohkQ |date=August 31, 2019 }}, ''New York Times'', November 15, 2009.</ref> Two [[United States House of Representatives|U.S. Representatives]], [[Joe Wilson (American politician)|Joe Wilson]] and [[Blaine Luetkemeyer]], both issued the same written statements: "One of the reasons I have long supported the U.S. biotechnology industry is that it is a homegrown success story that has been an engine of job creation in this country. Unfortunately, many of the largest companies that would seek to enter the biosimilar market have made their money by outsourcing their research to foreign countries like India." The statement was originally drafted by lobbyists for Genentech.